Johnson & Johnson
JNJJohnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange. Its common stock is a component of the Dow Jones Industrial Average, and the company is ranked No. 48 on the 2025 Fortune 500 list of the largest United States corporations. In 2025, the company was ranked 42nd in the Forbes Global 2000. Johnson & Johnson has a global workforce of approximately 138,000 employees who are led by the company's current chairman and chief executive officer, Joaquin Duato. Along with Microsoft, Johnson & Johnson is one of only two U.S.-based companies that has a prime credit rating of AAA from S&P Global.
Drugs in Pipeline
279
Phase 3 Programs
191
Upcoming Catalysts
3
Next Catalyst
Jul 15, 2026
12dMarket Overview
Stock performance and key metrics
4 upcoming, 2 past
JNJ Earnings Report
EPS Est: $2.83 | FQ end 2026-06 | Call: 2026-07-15 15:00:00
3 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How JNJ's past catalysts played out
PP3M 175 mg eq.
Schizophrenia
Group 1: Epoetin alfa
Myelodysplastic Syndromes
Lazertinib
Carcinoma, Non-Small-Cell Lung
PP6M
Schizophrenia
Etravirine
HIV Infections
Tapentadol (CG5503)
Arthralgia
Quetiapine
Bipolar Disorder
Canagliflozin 300 mg
Diabetes Mellitus, Type 2
CONCERTA (OROS methylphenidate hydrochloride)
Attention Deficit Disorder With Hyperactivity
OROS hydromorphone HCl
Pain
Peginterferon-alpha (PegIFNα-2a)
Hepatitis C, Chronic
Decitabine 20 mg/m^2
Leukemia, Myeloid, Acute
MVA-BN-Filo
Hemorrhagic Fever, Ebola
Genetic: AAV5-hRKp.RPGR Intermediate Dose
X-Linked Retinitis Pigmentosa
Ad26.Mos4.HIV
Healthy
Icotrokinra
Crohn Disease
Remifentanil
Anesthesia
Pegylated interferon alfa-2a
Chronic Hepatitis C Virus (HCV) Infection
Adalimumab
Psoriasis
Sirukumab 50 mg
Depressive Disorder, Major
Guselkumab dose 1
Hidradenitis Suppurativa
Aticaprant
Depressive Disorder, Major
Sitagliptin
Diabetes Mellitus, Type 2
Milvexian
Acute Coronary Syndrome
Fentanyl 1-day transdermal patch (Titration Phase)
Pain
ER OROS paliperidone
Schizophrenia
Esketamine (Intranasal Spray)
Treatment-resistant Depression
Efgartigimod
Myasthenia Gravis
Erdafitinib
Advanced Solid Tumor
rivaroxaban 15 mg
Atrial Fibrillation
Group 2 ustekinumab 130 mg
Crohn's Disease
5-Flurouracil
Squamous Cell Carcinoma of Head and Neck
CNTO 1959 50 mg
Psoriasis
ExPEC9V
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
NUCYNTA
Pain
Paliperidone palmitate (R092670)
Schizophrenia
Carboplatin
Carcinoma, Non-small-Cell Lung
paliperidone palmitate injection
Schizophrenia
TAR-210
Non-Muscle Invasive Bladder Neoplasms
Vinflunine
Urothelial Cancer
Guselkumab Dose 2
Colitis, Ulcerative
Dacarbazine
Advanced or Metastatic Liposarcoma or Leiomyosarcoma
galantamine ER
Alzheimer's Disease
Ustekinumab IV
Colitis, Ulcerative
DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC
HIV-1
Canagliflozin 100 mg
Diabetes Mellitus, Type 2
Ad26.ZEBOV
Ebola Virus Disease
Bendamustine hydrochloride
Chronic Lymphocytic Leukemia
Cetuximab
Colorectal Neoplasms
R331333 (referred to as JNS024 ER or CG5503)
Pain
Tramadol HCl/acetaminophen Extended Release
Low Back Pain
Genetic: AAV5-hRKp.RPGR
X-Linked Retinitis Pigmentosa
Efavirenz
Human Immunodeficiency Virus-type 1 Infection
Pegylated interferon alfa-2a (PegIFNα-2a)
Hepatitis C, Chronic
Golimumab
Arthritis, Juvenile
Guselkumab 100 mg
Psoriasis
Ribavirin
Chronic Hepatitis C
Pomalidomide
Relapsed or Refractory Multiple Myeloma
Risankizumab
Crohn Disease
Nipocalimab
Arthritis, Rheumatoid
Telaprevir
Hepatitis C, Chronic
Pegylated interferon alpha-2a
Hepatitis C Virus Genotype-1
ustekinumab 45 mg
Arthritis, Psoriatic
Durogesic® (fentanyl transdermal drug delivery system)
Chronic Pain
Paliperidone ER OROS®
Schizophrenia
Prednisone
Prostate Neoplasms
ER OROS paliperidone and Olanzapine
Acute Schizophrenia
Risperidone, oral tablets
Bipolar Disorders
Carfilzomib
Relapsed or Refractory Multiple Myeloma
Canagliflozin
Diabetes Mellitus, Type 2
Abiraterone acetate
Prostate Neoplasms
Ad26.ZEBOV 5*10^10 viral particles (vp)
Healthy
Intravenous immunoglobulins (IVIG)
Thrombocytopenia, Neonatal Alloimmune
Esketamine 28 mg
Depressive Disorder, Major
methylphenidate
Depressive Disorder, Major
Sirukumab
Arthritis, Rheumatoid
Daratumumab IV
Multiple Myeloma
Sitagliptin 100 mg
Diabetes Mellitus, Type 2
Paliperidone extended release (ER)
Schizophrenia
Ad26.RSV.PreF-based Vaccine
Respiratory Syncytial Virus Prevention
Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF
Respiratory Syncytial Viruses
D/C/F/TAF
Human Immunodeficiency Virus Type 1
Nesiritide
Heart Decompensation
Fumaric Acid Esters
Psoriasis
Risperidone, long-acting injectable
Schizophrenia
Temsirolimus
Mantle Cell Lymphoma
Sofosbuvir
Chronic Hepatitis C
Epo-alpha
Resuscitation
Tapentadol (CG5503) Extended Release (ER)
Pain
Test acetaminophen
Post-operative Dental Pain
risperidone oral tablets
Anxiety Disorders
Doxorubicin
Sarcoma
CG 5503;tapentadol
Osteoarthritis
tapentadol (CG5503) ER
Low Back Pain
levofloxacin
Pneumonia
Rivaroxaban
Atrial Fibrillation
tapentadol (CG5503) Immediate Release IR
Low Back Pain
levofloxacin, azithromycin, amoxicillin/clavulanate
Bronchitis
Acetaminophen/Naproxen Sodium Fixed Combination
Pain
Bortezomib
Multiple Myeloma
Paliperidone extended-release
Bipolar Disorder
Risperdal Consta
Bipolar Disorder
Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)
Multiple Myeloma
paliperidone ER Oros
Schizophrenia
Gemcitabine with R115777
Pancreatic Neoplasms
Mebendazole
Healthy Volunteers
Dapoxetine
Erectile Dysfunction
F# 13418-148 Eye Drops
Ophthalmic Solutions
Rivaroxaban 2.5 mg
Acute Coronary Syndrome
Dexamethasone
Endometrial Neoplasms
levofloxacin; amoxicillin/clavulanate
Otitis Media
Paliperidone ER
Schizophrenia
topiramate
Essential Tremor
doripenem
Pneumonia
Trabectedin
Ovarian Cancer
risperidone
Bipolar Disorders
norelgestromin + ethinyl estradiol
Contraception
Rabeprazole sodium 5 mg
Gastroesophageal Reflux
Tapentadol extended release (ER)
Diabetic Peripheral Neuropathy
Oxycodone CR
Osteoarthritis, Hip
oxycodone IR
Joint Diseases
Thalidomide
Multiple Myeloma
oxycodone
Osteoarthritis, Knee
CG5503 IR;tapentadol
Arthralgia
Topiramate; Carbamazepine; Valproate
Epilepsy
levofloxacin; imipenem/cilastitin
Nosocomial Pneumonia
Pancrease MT 10.5, or MT 21
Exocrine Pancreatic Insufficiency
Colloidal Oatmeal Cream
Eczema
ivermectin
Lice Infestations
Paliperidone palmitate 25 mg eq.
Schizophrenia
JNJ-90301900 (NBTXR3)
Locally Advanced Head and Neck Squamous Cell Carcinoma
norelgestromin + ethinyl estradiol; mercilon
Contraception
Extended-release galantamine hydrobromide
Schizophrenia
acetaminophen
Osteoarthritis of the Knee
Olanzapine
Bipolar Disorder
Test naproxen sodium tablet
Post-operative Dental Pain
galantamine
Alzheimer's Disease
5% Minoxidil Topical Foam
Androgenetic Alopecia
Imonogas
Functional Dyspepsia
rabeprazole
Gastroesophageal Reflux Disease (GERD)
galantamine hydrobromide
Alzheimer Disease
Hydromorphone HCl
Pain
topiramate, phenytoin
Epilepsy
Paliperidone palmitate
Schizophrenia
Docetaxel
Breast Cancer
norelgestromin + ethinyl estradiol; triphasil.
Contraception
doripenum
Urinary Tract Infections
acetaminophen extended release
Osteoarthritis
CG5503
Diabetic Neuropathy
Duragesic® (fentanyl) Therapeutic Transdermal System (TTS)
Chronic Pain
CG5503 IR; tapentadol
Osteoarthritis
tramadol, acetaminophen
Diabetic Neuropathies
5% Minoxidil
Alopecia
naproxen
Osteoarthritis, Hip
risperidone; quetiapine
Bipolar Disorder
minoxidil
Androgenetic Alopecia
PDE5I (phosphodiesterase-5 inhibitor)
Erectile Dysfunction
Extended Release OROS® Paliperidone
Schizophrenia
acetaminophen Tablet
Post Operative Dental Pain
Paliperidone
Schizophrenia
Tipifarnib;Zarnestra; R115777
Acute Myeloid Leukemia
Epoetin alfa 3 times weekly /once weekly
Anemia
epoetin alfa
Chronic Kidney Disease
Risperidone long-acting injectable
Schizophrenia
Prucalopride
Constipation
topiramate, propranolol
Migraine
Ibrutinib
Leukemia, Lymphocytic, Chronic, B-Cell
TAR-200
Non-Muscle Invasive Bladder Neoplasms
Levetiracetam
Epilepsy
Cilta-cel
Multiple Myeloma
Talquetamab
Multiple Myeloma
TMC435
Hepatitis C
Risperidone Long-acting Injectable (LAI) 25 mg
Schizophrenia
Tramadol Hydrochloride (HCL) plus Acetaminophen (JNS013)
Chronic Pain
JNJ-77242113
Plaque Psoriasis
Simeprevir
Hepatitis C Virus Infection
Fentanyl
Postherpetic Neuralgia
No treatment
Hepatitis C
JNJ-63723283
Multiple Myeloma
Guselkumab
Psoriasis
Daratumumab
Multiple Myeloma
Fulranumab 1 mg
Osteoarthritis
Ad26.COV2.S
Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol
Macitentan
Pulmonary Arterial Hypertension
Rilpivirine
HIV-1
Amivantamab
Carcinoma, Non-Small-Cell Lung
Sirukumab 100 mg
Arthritis, Rheumatoid
Seltorexant
Depressive Disorder, Major
Ustekinumab
Crohn Disease
Teclistamab
Multiple Myeloma
Ustekinumab 90 mg SC q8w
Crohn's Disease
R228060
Major Depressive Disorder
Atomoxetine 80 mg/d
Attention Deficit Hyperactivity Disorder
JNJ-42847922
Depressive Disorder, Major
Investigational Lubricating Eye Drop in a Novelia® bottle
Dry Eye
JNJ-39220675
Allergic Rhinitis
Acetaminophen/naproxen sodium Dose A
Pain
JNJ-90301900
Carcinoma, Non-Small-Cell Lung
Experimental Product 1% Colloidal Oatmeal Balm
Atopic Dermatitis
Yondelis
Liposarcoma
JNJ16269110
Diabetes Mellitus, Type 2
Cetrelimab
Urinary Bladder Neoplasms
ibuprofen; pseudoephedrine HCl
Enuresis
Standard-of-care treatment
Systemic Lupus Erythematosus
Atazanavir (ATV) 300 mg
HIV Infections
JNJ-42165279
Depressive Disorder
ExPEC4V (4 : 4 : 4 : 4)
Healthy
Paclitaxel
Squamous Cell Carcinoma of Head and Neck
Antipsychotic medication
Schizophrenia
Escitalopram
Major Depressive Disorder
Canagliflozin (JNJ-28431754)
Diabetes Mellitus, Type II
RWJ-445380 100 mg
Rheumatoid Arthritis
tapentadol HCl
Pain
JNJ-81201887
Geographic Atrophy
Capmatinib
Carcinoma, Non-Small-Cell Lung
JNJ-37822681
Schizophrenia
CNTO 1959
Palmoplantaris Pustulosis
Ketamine
Major Depressive Disorder
JNJ-40411813
Major Depressive Disorder
sIPV
Healthy
Erdafitinib Intravesical Delivery System
Non-Muscle Invasive Bladder Neoplasms
Ad26.RSV.preF (1*10^11 vp)
Respiratory Syncytial Viruses
R092670
Schizophrenia
Abiraterone
Prostate Cancer
Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)
Multiple Myeloma
Esketamine
Major Depressive Disorder
Lenalidomide
Lymphoma, Mantle-Cell
Intranasal esketamine (28 mg)
Depression
JNJ-41443532
Diabetes Mellitus, Type 2
Montelukast
Carcinoma, Non-Small-Cell Lung
Canagliflozin 50 mg
Diabetes Mellitus, Type 2
ET743
Breast Neoplasms
JNJ-39588146 5 ng/kg/min
Heart Failure
tipifarnib (R115777)
Leukemia, Nonlymphocytic, Acute
JNJ39758979
Asthma
Nesiritide (1+0.01)
Heart Failure, Congestive
JNJ-73763989
Hepatitis B, Chronic
JNJ-63623872
Influenza A Virus
AL-335
Hepatitis C, Chronic
Imipenem/cilastatin
Pneumonia, Ventilator-Associated
JNJ-31001074
Attention Deficit Hyperactivity Disorder
JNJ-40346527
Arthritis, Rheumatoid
NNC0142-0002
Inflammation
RSV Vaccine
Healthy
JNJ 40929837
Asthma
JNJ-64304500
Crohn Disease
R209130
Schizophrenia
NNC 0142-0000-0002
Inflammation
Tapentadol
Pain
Decitabine
Myelodysplastic Syndrome
Cyclophosphamide
Multiple Myeloma
R256918
Obesity
Amivantamab IV
Advanced or Metastatic Colorectal Cancer
ZARNESTRA, tipifarnib, R115777
Acute Myeloid Leukemia
Glucocorticoids
Myositis
TMC207 (bedaquiline)
Tuberculosis, Multidrug-Resistant
CNTO 2476 3.0 x 10^5 cells
Visual Acuity
Apalutamide
Salivary Gland Neoplasms
JNJ-17166864
Allergic Rhinitis
Acetaminophen (ACE) (1000 mg)
Dental Pain
VX-787 300 mg
Influenza A
Daratumumab 16 mg/kg (Part 1)
Multiple Myeloma
Ketoconazole
Neoplasm Metastases
Fluarix
Healthy
Olomorasib
Carcinoma, Non-Small-Cell Lung
PROCRIT (Epoetin alfa)
Anemia
Ad26.RSV.preF
Respiratory Syncytial Virus
Venetoclax
Leukemia, Lymphocytic, Chronic, B-Cell
JNJ 49095397
Chronic Obstructive Pulmonary Disease
Siltuximab
Multicentric Castleman's Disease
Ad26.Mos.HIV
Healthy
T2-18C3 therapeutic antibody
Type 2 Diabetes
Blink® Tears eye drops in a multidose bottle
Visual Acuity
JNJ-64565111 Dose Level 1
Obesity and Diabetes Mellitus, Type 2
Dupilumab
Dermatitis, Atopic
MVA-Mosaic
Human Immunodeficiency Virus
JNJ-53718678
Respiratory Syncytial Virus Infections
440 mg naproxen sodium with 1000 mg acetaminophen
Pain
JNJ-26489112
Photosensitive Epilepsy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PP3M 175 mg eq. | Phase 3 | Schizophrenia | - | - |
Group 1: Epoetin alfa | Phase 3 | Myelodysplastic Syndromes | - | - |
Lazertinib | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
PP6M | Phase 3 | Schizophrenia | - | - |
Etravirine | Phase 3 | HIV Infections | - | - |
Tapentadol (CG5503) | Phase 3 | Arthralgia | - | - |
Quetiapine | Phase 3 | Bipolar Disorder | - | - |
Canagliflozin 300 mg | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
CONCERTA (OROS methylphenidate hydrochloride) | Phase 3 | Attention Deficit Disorder With Hyperactivity | - | - |
OROS hydromorphone HCl | Phase 3 | Pain | - | - |
Peginterferon-alpha (PegIFNα-2a) | Phase 3 | Hepatitis C, Chronic | - | - |
Decitabine 20 mg/m^2 | Phase 3 | Leukemia, Myeloid, Acute | - | - |
MVA-BN-Filo | Phase 3 | Hemorrhagic Fever, Ebola | - | - |
Genetic: AAV5-hRKp.RPGR Intermediate Dose | Phase 3 | X-Linked Retinitis Pigmentosa | - | - |
Ad26.Mos4.HIV | Phase 3 | Healthy | - | - |
Icotrokinra | Phase 3 | Crohn Disease | - | - |
Remifentanil | Phase 3 | Anesthesia | - | - |
Pegylated interferon alfa-2a | Phase 3 | Chronic Hepatitis C Virus (HCV) Infection | - | - |
Adalimumab | Phase 3 | Psoriasis | - | - |
Sirukumab 50 mg | Phase 3 | Depressive Disorder, Major | - | - |
Guselkumab dose 1 | Phase 3 | Hidradenitis Suppurativa | - | - |
Aticaprant | Phase 3 | Depressive Disorder, Major | - | - |
Sitagliptin | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Milvexian | Phase 3 | Acute Coronary Syndrome | - | - |
Fentanyl 1-day transdermal patch (Titration Phase) | Phase 3 | Pain | - | - |
ER OROS paliperidone | Phase 3 | Schizophrenia | - | - |
Esketamine (Intranasal Spray) | Phase 3 | Treatment-resistant Depression | - | - |
Efgartigimod | Phase 3 | Myasthenia Gravis | - | - |
Erdafitinib | Phase 3 | Advanced Solid Tumor | - | - |
rivaroxaban 15 mg | Phase 3 | Atrial Fibrillation | - | - |
Group 2 ustekinumab 130 mg | Phase 3 | Crohn's Disease | - | - |
5-Flurouracil | Phase 3 | Squamous Cell Carcinoma of Head and Neck | - | - |
CNTO 1959 50 mg | Phase 3 | Psoriasis | - | - |
ExPEC9V | Phase 3 | Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention | - | - |
NUCYNTA | Phase 3 | Pain | - | - |
Paliperidone palmitate (R092670) | Phase 3 | Schizophrenia | - | - |
Carboplatin | Phase 3 | Carcinoma, Non-small-Cell Lung | - | - |
paliperidone palmitate injection | Phase 3 | Schizophrenia | - | - |
TAR-210 | Phase 3 | Non-Muscle Invasive Bladder Neoplasms | - | - |
Vinflunine | Phase 3 | Urothelial Cancer | - | - |
Guselkumab Dose 2 | Phase 3 | Colitis, Ulcerative | - | - |
Dacarbazine | Phase 3 | Advanced or Metastatic Liposarcoma or Leiomyosarcoma | - | - |
galantamine ER | Phase 3 | Alzheimer's Disease | - | - |
Ustekinumab IV | Phase 3 | Colitis, Ulcerative | - | - |
DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC | Phase 3 | HIV-1 | - | - |
Canagliflozin 100 mg | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Ad26.ZEBOV | Phase 3 | Ebola Virus Disease | - | - |
Bendamustine hydrochloride | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
Cetuximab | Phase 3 | Colorectal Neoplasms | - | - |
R331333 (referred to as JNS024 ER or CG5503) | Phase 3 | Pain | - | - |
Tramadol HCl/acetaminophen Extended Release | Phase 3 | Low Back Pain | - | - |
Genetic: AAV5-hRKp.RPGR | Phase 3 | X-Linked Retinitis Pigmentosa | - | - |
Efavirenz | Phase 3 | Human Immunodeficiency Virus-type 1 Infection | - | - |
Pegylated interferon alfa-2a (PegIFNα-2a) | Phase 3 | Hepatitis C, Chronic | - | - |
Golimumab | Phase 3 | Arthritis, Juvenile | - | - |
Guselkumab 100 mg | Phase 3 | Psoriasis | - | - |
Ribavirin | Phase 3 | Chronic Hepatitis C | - | - |
Pomalidomide | Phase 3 | Relapsed or Refractory Multiple Myeloma | - | - |
Risankizumab | Phase 3 | Crohn Disease | - | - |
Nipocalimab | Phase 3 | Arthritis, Rheumatoid | - | - |
Telaprevir | Phase 3 | Hepatitis C, Chronic | - | - |
Pegylated interferon alpha-2a | Phase 3 | Hepatitis C Virus Genotype-1 | - | - |
ustekinumab 45 mg | Phase 3 | Arthritis, Psoriatic | - | - |
Durogesic® (fentanyl transdermal drug delivery system) | Phase 3 | Chronic Pain | - | - |
Paliperidone ER OROS® | Phase 3 | Schizophrenia | - | - |
Prednisone | Phase 3 | Prostate Neoplasms | - | - |
ER OROS paliperidone and Olanzapine | Phase 3 | Acute Schizophrenia | - | - |
Risperidone, oral tablets | Phase 3 | Bipolar Disorders | - | - |
Carfilzomib | Phase 3 | Relapsed or Refractory Multiple Myeloma | - | - |
Canagliflozin | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Abiraterone acetate | Phase 3 | Prostate Neoplasms | - | - |
Ad26.ZEBOV 5*10^10 viral particles (vp) | Phase 3 | Healthy | - | - |
Intravenous immunoglobulins (IVIG) | Phase 3 | Thrombocytopenia, Neonatal Alloimmune | - | - |
Esketamine 28 mg | Phase 3 | Depressive Disorder, Major | - | - |
methylphenidate | Phase 3 | Depressive Disorder, Major | - | - |
Sirukumab | Phase 3 | Arthritis, Rheumatoid | - | - |
Daratumumab IV | Phase 3 | Multiple Myeloma | - | - |
Sitagliptin 100 mg | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Paliperidone extended release (ER) | Phase 3 | Schizophrenia | - | - |
Ad26.RSV.PreF-based Vaccine | Phase 3 | Respiratory Syncytial Virus Prevention | - | - |
Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF | Phase 3 | Respiratory Syncytial Viruses | - | - |
D/C/F/TAF | Phase 3 | Human Immunodeficiency Virus Type 1 | - | - |
Nesiritide | Phase 3 | Heart Decompensation | - | - |
Fumaric Acid Esters | Phase 3 | Psoriasis | - | - |
Risperidone, long-acting injectable | Phase 3 | Schizophrenia | - | - |
Temsirolimus | Phase 3 | Mantle Cell Lymphoma | - | - |
Sofosbuvir | Phase 3 | Chronic Hepatitis C | - | - |
Epo-alpha | Phase 3 | Resuscitation | - | - |
Tapentadol (CG5503) Extended Release (ER) | Phase 3 | Pain | - | - |
Test acetaminophen | Phase 3 | Post-operative Dental Pain | - | Patent 2032 |
risperidone oral tablets | Phase 3 | Anxiety Disorders | - | - |
Doxorubicin | Phase 3 | Sarcoma | - | - |
CG 5503;tapentadol | Phase 3 | Osteoarthritis | - | - |
tapentadol (CG5503) ER | Phase 3 | Low Back Pain | - | - |
levofloxacin | Phase 3 | Pneumonia | - | |
Rivaroxaban | Phase 3 | Atrial Fibrillation | - | Patent 2034 |
tapentadol (CG5503) Immediate Release IR | Phase 3 | Low Back Pain | - | - |
levofloxacin, azithromycin, amoxicillin/clavulanate | Phase 3 | Bronchitis | - | - |
Acetaminophen/Naproxen Sodium Fixed Combination | Phase 3 | Pain | - | - |
Bortezomib | Phase 3 | Multiple Myeloma | - | Patent 2042 |
Paliperidone extended-release | Phase 3 | Bipolar Disorder | - | - |
Risperdal Consta | Phase 3 | Bipolar Disorder | - | - |
Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD) | Phase 3 | Multiple Myeloma | - | - |
paliperidone ER Oros | Phase 3 | Schizophrenia | - | |
Gemcitabine with R115777 | Phase 3 | Pancreatic Neoplasms | - | - |
Mebendazole | Phase 3 | Healthy Volunteers | - | |
Dapoxetine | Phase 3 | Erectile Dysfunction | - | - |
F# 13418-148 Eye Drops | Phase 3 | Ophthalmic Solutions | - | - |
Rivaroxaban 2.5 mg | Phase 3 | Acute Coronary Syndrome | - | Patent 2034 |
Dexamethasone | Phase 3 | Endometrial Neoplasms | - | Patent 2041 |
levofloxacin; amoxicillin/clavulanate | Phase 3 | Otitis Media | - | - |
Paliperidone ER | Phase 3 | Schizophrenia | - | |
topiramate | Phase 3 | Essential Tremor | - | Patent 2040 |
doripenem | Phase 3 | Pneumonia | - | |
Trabectedin | Phase 3 | Ovarian Cancer | - | Patent 2043 |
risperidone | Phase 3 | Bipolar Disorders | - | Patent 2042 |
norelgestromin + ethinyl estradiol | Phase 3 | Contraception | - | - |
Rabeprazole sodium 5 mg | Phase 3 | Gastroesophageal Reflux | - | |
Tapentadol extended release (ER) | Phase 3 | Diabetic Peripheral Neuropathy | - | - |
Oxycodone CR | Phase 3 | Osteoarthritis, Hip | - | Patent 2036 |
oxycodone IR | Phase 3 | Joint Diseases | - | - |
Thalidomide | Phase 3 | Multiple Myeloma | - | - |
oxycodone | Phase 3 | Osteoarthritis, Knee | - | - |
CG5503 IR;tapentadol | Phase 3 | Arthralgia | - | - |
Topiramate; Carbamazepine; Valproate | Phase 3 | Epilepsy | - | - |
levofloxacin; imipenem/cilastitin | Phase 3 | Nosocomial Pneumonia | - | - |
Pancrease MT 10.5, or MT 21 | Phase 3 | Exocrine Pancreatic Insufficiency | - | - |
Colloidal Oatmeal Cream | Phase 3 | Eczema | - | - |
ivermectin | Phase 3 | Lice Infestations | - | - |
Paliperidone palmitate 25 mg eq. | Phase 3 | Schizophrenia | - | - |
JNJ-90301900 (NBTXR3) | Phase 3 | Locally Advanced Head and Neck Squamous Cell Carcinoma | - | - |
norelgestromin + ethinyl estradiol; mercilon | Phase 3 | Contraception | - | - |
Extended-release galantamine hydrobromide | Phase 3 | Schizophrenia | - | - |
acetaminophen | Phase 3 | Osteoarthritis of the Knee | - | - |
Olanzapine | Phase 3 | Bipolar Disorder | - | - |
Test naproxen sodium tablet | Phase 3 | Post-operative Dental Pain | - | - |
galantamine | Phase 3 | Alzheimer's Disease | - | - |
5% Minoxidil Topical Foam | Phase 3 | Androgenetic Alopecia | - | - |
Imonogas | Phase 3 | Functional Dyspepsia | - | - |
rabeprazole | Phase 3 | Gastroesophageal Reflux Disease (GERD) | - | - |
galantamine hydrobromide | Phase 3 | Alzheimer Disease | - | - |
Hydromorphone HCl | Phase 3 | Pain | - | - |
topiramate, phenytoin | Phase 3 | Epilepsy | - | - |
Paliperidone palmitate | Phase 3 | Schizophrenia | - | - |
Docetaxel | Phase 3 | Breast Cancer | - | - |
norelgestromin + ethinyl estradiol; triphasil. | Phase 3 | Contraception | - | - |
doripenum | Phase 3 | Urinary Tract Infections | - | - |
acetaminophen extended release | Phase 3 | Osteoarthritis | - | - |
CG5503 | Phase 3 | Diabetic Neuropathy | - | - |
Duragesic® (fentanyl) Therapeutic Transdermal System (TTS) | Phase 3 | Chronic Pain | - | - |
CG5503 IR; tapentadol | Phase 3 | Osteoarthritis | - | - |
tramadol, acetaminophen | Phase 3 | Diabetic Neuropathies | - | - |
5% Minoxidil | Phase 3 | Alopecia | - | - |
naproxen | Phase 3 | Osteoarthritis, Hip | - | - |
risperidone; quetiapine | Phase 3 | Bipolar Disorder | - | - |
minoxidil | Phase 3 | Androgenetic Alopecia | - | - |
PDE5I (phosphodiesterase-5 inhibitor) | Phase 3 | Erectile Dysfunction | - | - |
Extended Release OROS® Paliperidone | Phase 3 | Schizophrenia | - | - |
acetaminophen Tablet | Phase 3 | Post Operative Dental Pain | - | - |
Paliperidone | Phase 3 | Schizophrenia | - | - |
Tipifarnib;Zarnestra; R115777 | Phase 3 | Acute Myeloid Leukemia | - | - |
Epoetin alfa 3 times weekly /once weekly | Phase 3 | Anemia | - | - |
epoetin alfa | Phase 3 | Chronic Kidney Disease | - | - |
Risperidone long-acting injectable | Phase 3 | Schizophrenia | - | - |
Prucalopride | Phase 3 | Constipation | - | - |
topiramate, propranolol | Phase 3 | Migraine | - | - |
Ibrutinib | Phase 3 | Leukemia, Lymphocytic, Chronic, B-Cell | - | - |
TAR-200 | Phase 3 | Non-Muscle Invasive Bladder Neoplasms | - | - |
Levetiracetam | Phase 3 | Epilepsy | - | - |
Cilta-cel | Phase 3 | Multiple Myeloma | - | - |
Talquetamab | Phase 3 | Multiple Myeloma | - | - |
TMC435 | Phase 3 | Hepatitis C | - | - |
Risperidone Long-acting Injectable (LAI) 25 mg | Phase 3 | Schizophrenia | - | - |
Tramadol Hydrochloride (HCL) plus Acetaminophen (JNS013) | Phase 3 | Chronic Pain | - | - |
JNJ-77242113 | Phase 3 | Plaque Psoriasis | - | - |
Simeprevir | Phase 3 | Hepatitis C Virus Infection | - | - |
Fentanyl | Phase 3 | Postherpetic Neuralgia | - | - |
No treatment | Phase 3 | Hepatitis C | - | - |
JNJ-63723283 | Phase 3 | Multiple Myeloma | - | - |
Guselkumab | Phase 3 | Psoriasis | - | - |
Daratumumab | Phase 3 | Multiple Myeloma | - | - |
Fulranumab 1 mg | Phase 3 | Osteoarthritis | - | - |
Ad26.COV2.S | Phase 3 | Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol | - | - |
Macitentan | Phase 3 | Pulmonary Arterial Hypertension | - | - |
Rilpivirine | Phase 3 | HIV-1 | - | - |
Amivantamab | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Sirukumab 100 mg | Phase 3 | Arthritis, Rheumatoid | - | - |
Seltorexant | Phase 3 | Depressive Disorder, Major | - | - |
Ustekinumab | Phase 3 | Crohn Disease | - | - |
Teclistamab | Phase 3 | Multiple Myeloma | - | - |
Ustekinumab 90 mg SC q8w | Phase 3 | Crohn's Disease | - | - |
R228060 | Phase 2 | Major Depressive Disorder | - | - |
Atomoxetine 80 mg/d | Phase 2 | Attention Deficit Hyperactivity Disorder | - | - |
JNJ-42847922 | Phase 2 | Depressive Disorder, Major | - | - |
Investigational Lubricating Eye Drop in a Novelia® bottle | Phase 2 | Dry Eye | - | - |
JNJ-39220675 | Phase 2 | Allergic Rhinitis | - | - |
Acetaminophen/naproxen sodium Dose A | Phase 2 | Pain | - | - |
JNJ-90301900 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Experimental Product 1% Colloidal Oatmeal Balm | Phase 2 | Atopic Dermatitis | - | - |
Yondelis | Phase 2 | Liposarcoma | - | - |
JNJ16269110 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Cetrelimab | Phase 2 | Urinary Bladder Neoplasms | - | - |
ibuprofen; pseudoephedrine HCl | Phase 2 | Enuresis | - | - |
Standard-of-care treatment | Phase 2 | Systemic Lupus Erythematosus | - | - |
Atazanavir (ATV) 300 mg | Phase 2 | HIV Infections | - | - |
JNJ-42165279 | Phase 2 | Depressive Disorder | - | - |
ExPEC4V (4 : 4 : 4 : 4) | Phase 2 | Healthy | - | - |
Paclitaxel | Phase 2 | Squamous Cell Carcinoma of Head and Neck | - | - |
Antipsychotic medication | Phase 2 | Schizophrenia | - | - |
Escitalopram | Phase 2 | Major Depressive Disorder | - | - |
Canagliflozin (JNJ-28431754) | Phase 2 | Diabetes Mellitus, Type II | - | - |
RWJ-445380 100 mg | Phase 2 | Rheumatoid Arthritis | - | - |
tapentadol HCl | Phase 2 | Pain | - | - |
JNJ-81201887 | Phase 2 | Geographic Atrophy | - | - |
Capmatinib | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
JNJ-37822681 | Phase 2 | Schizophrenia | - | - |
CNTO 1959 | Phase 2 | Palmoplantaris Pustulosis | - | - |
Ketamine | Phase 2 | Major Depressive Disorder | - | - |
JNJ-40411813 | Phase 2 | Major Depressive Disorder | - | - |
sIPV | Phase 2 | Healthy | - | - |
Erdafitinib Intravesical Delivery System | Phase 2 | Non-Muscle Invasive Bladder Neoplasms | - | - |
Ad26.RSV.preF (1*10^11 vp) | Phase 2 | Respiratory Syncytial Viruses | - | - |
R092670 | Phase 2 | Schizophrenia | - | - |
Abiraterone | Phase 2 | Prostate Cancer | - | - |
Lymphodepleting Therapy (Cyclophosphamide and Fludarabine) | Phase 2 | Multiple Myeloma | - | - |
Esketamine | Phase 2 | Major Depressive Disorder | - | - |
Lenalidomide | Phase 2 | Lymphoma, Mantle-Cell | - | - |
Intranasal esketamine (28 mg) | Phase 2 | Depression | - | - |
JNJ-41443532 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Montelukast | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Canagliflozin 50 mg | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
ET743 | Phase 2 | Breast Neoplasms | - | - |
JNJ-39588146 5 ng/kg/min | Phase 2 | Heart Failure | - | - |
tipifarnib (R115777) | Phase 2 | Leukemia, Nonlymphocytic, Acute | - | - |
JNJ39758979 | Phase 2 | Asthma | - | - |
Nesiritide (1+0.01) | Phase 2 | Heart Failure, Congestive | - | - |
JNJ-73763989 | Phase 2 | Hepatitis B, Chronic | - | - |
JNJ-63623872 | Phase 2 | Influenza A Virus | - | - |
AL-335 | Phase 2 | Hepatitis C, Chronic | - | - |
Imipenem/cilastatin | Phase 2 | Pneumonia, Ventilator-Associated | - | - |
JNJ-31001074 | Phase 2 | Attention Deficit Hyperactivity Disorder | - | - |
JNJ-40346527 | Phase 2 | Arthritis, Rheumatoid | - | - |
NNC0142-0002 | Phase 2 | Inflammation | - | - |
RSV Vaccine | Phase 2 | Healthy | - | - |
JNJ 40929837 | Phase 2 | Asthma | - | - |
JNJ-64304500 | Phase 2 | Crohn Disease | - | - |
R209130 | Phase 2 | Schizophrenia | - | - |
NNC 0142-0000-0002 | Phase 2 | Inflammation | - | - |
Tapentadol | Phase 2 | Pain | - | - |
Decitabine | Phase 2 | Myelodysplastic Syndrome | - | - |
Cyclophosphamide | Phase 2 | Multiple Myeloma | - | - |
R256918 | Phase 2 | Obesity | - | - |
Amivantamab IV | Phase 2 | Advanced or Metastatic Colorectal Cancer | - | - |
ZARNESTRA, tipifarnib, R115777 | Phase 2 | Acute Myeloid Leukemia | - | - |
Glucocorticoids | Phase 2 | Myositis | - | - |
TMC207 (bedaquiline) | Phase 2 | Tuberculosis, Multidrug-Resistant | - | - |
CNTO 2476 3.0 x 10^5 cells | Phase 2 | Visual Acuity | - | - |
Apalutamide | Phase 2 | Salivary Gland Neoplasms | - | - |
JNJ-17166864 | Phase 2 | Allergic Rhinitis | - | - |
Acetaminophen (ACE) (1000 mg) | Phase 2 | Dental Pain | - | - |
VX-787 300 mg | Phase 2 | Influenza A | - | - |
Daratumumab 16 mg/kg (Part 1) | Phase 2 | Multiple Myeloma | - | - |
Ketoconazole | Phase 2 | Neoplasm Metastases | - | - |
Fluarix | Phase 2 | Healthy | - | - |
Olomorasib | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
PROCRIT (Epoetin alfa) | Phase 2 | Anemia | - | - |
Ad26.RSV.preF | Phase 2 | Respiratory Syncytial Virus | - | - |
Venetoclax | Phase 2 | Leukemia, Lymphocytic, Chronic, B-Cell | - | - |
JNJ 49095397 | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
Siltuximab | Phase 2 | Multicentric Castleman's Disease | - | - |
Ad26.Mos.HIV | Phase 2 | Healthy | - | - |
T2-18C3 therapeutic antibody | Phase 2 | Type 2 Diabetes | - | - |
Blink® Tears eye drops in a multidose bottle | Phase 2 | Visual Acuity | - | - |
JNJ-64565111 Dose Level 1 | Phase 2 | Obesity and Diabetes Mellitus, Type 2 | - | - |
Dupilumab | Phase 2 | Dermatitis, Atopic | - | - |
MVA-Mosaic | Phase 2 | Human Immunodeficiency Virus | - | - |
JNJ-53718678 | Phase 2 | Respiratory Syncytial Virus Infections | - | - |
440 mg naproxen sodium with 1000 mg acetaminophen | Phase 2 | Pain | - | - |
JNJ-26489112 | Phase 2 | Photosensitive Epilepsy | - | - |
Schizophrenia
4 drugs in this indication
Bipolar Disorder
3 drugs in this indication
Pain
2 drugs in this indication
Pneumonia
2 drugs in this indication
Diabetes Mellitus, Type 2
2 drugs in this indication
Multiple Myeloma
2 drugs in this indication
Low Back Pain
2 drugs in this indication
Major Depressive Disorder
1 drug in this indication
Ophthalmic Solutions
1 drug in this indication
Acute Coronary Syndrome
1 drug in this indication
Endometrial Neoplasms
1 drug in this indication
Post-operative Dental Pain
1 drug in this indication
Bronchitis
1 drug in this indication
Anxiety Disorders
1 drug in this indication
Chronic Kidney Disease
1 drug in this indication
Healthy Volunteers
1 drug in this indication
Ovarian Cancer
1 drug in this indication
Sarcoma
1 drug in this indication
Osteoarthritis
1 drug in this indication
Erectile Dysfunction
1 drug in this indication
Bipolar Disorders
1 drug in this indication
Atrial Fibrillation
1 drug in this indication
Otitis Media
1 drug in this indication
Contraception
1 drug in this indication
Alzheimer's Disease
1 drug in this indication
Carcinoma, Non-Small-Cell Lung
1 drug in this indication
Enuresis
1 drug in this indication
Pancreatic Neoplasms
1 drug in this indication
Gastroesophageal Reflux
1 drug in this indication
Atopic Dermatitis
1 drug in this indication
Essential Tremor
1 drug in this indication
Joint Diseases
1 drug in this indication
Sprains and Strains
1 drug in this indication
Diabetic Peripheral Neuropathy
1 drug in this indication
Heart Failure
1 drug in this indication
Osteoarthritis, Hip
1 drug in this indication
Leukemia, Nonlymphocytic, Acute
1 drug in this indication
Asthma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Johnson & Johnson's drug pipeline?→
CatalystAlert tracks 279 drug candidates in Johnson & Johnson's (JNJ) pipeline across Phase 3, Phase 2. Its lead program is PP3M 175 mg eq. (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Johnson & Johnson's next FDA catalyst?→
Johnson & Johnson's (JNJ) next tracked catalyst is a Earnings expected July 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track JNJ biotech catalysts?→
Add JNJ to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Johnson & Johnson's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.